AU2017238647B2 - Treatment of cancer with TG02 - Google Patents

Treatment of cancer with TG02 Download PDF

Info

Publication number
AU2017238647B2
AU2017238647B2 AU2017238647A AU2017238647A AU2017238647B2 AU 2017238647 B2 AU2017238647 B2 AU 2017238647B2 AU 2017238647 A AU2017238647 A AU 2017238647A AU 2017238647 A AU2017238647 A AU 2017238647A AU 2017238647 B2 AU2017238647 B2 AU 2017238647B2
Authority
AU
Australia
Prior art keywords
cancer
carcinoma
cell
inhibitor
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017238647A
Other languages
English (en)
Other versions
AU2017238647A1 (en
Inventor
Thomas M. Estok
Tracy PARROTT
Eckard Weber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cothera Bioscience Inc
Original Assignee
Cothera Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cothera Bioscience Inc filed Critical Cothera Bioscience Inc
Publication of AU2017238647A1 publication Critical patent/AU2017238647A1/en
Application granted granted Critical
Publication of AU2017238647B2 publication Critical patent/AU2017238647B2/en
Assigned to Cothera Bioscience, Inc. reassignment Cothera Bioscience, Inc. Request for Assignment Assignors: TRAGARA PHARMACEUTICALS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2017238647A 2016-03-24 2017-03-24 Treatment of cancer with TG02 Active AU2017238647B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662312712P 2016-03-24 2016-03-24
US62/312,712 2016-03-24
US201662423468P 2016-11-17 2016-11-17
US62/423,468 2016-11-17
PCT/US2017/023965 WO2017165732A1 (en) 2016-03-24 2017-03-24 Treatment of cancer with tg02

Publications (2)

Publication Number Publication Date
AU2017238647A1 AU2017238647A1 (en) 2018-10-25
AU2017238647B2 true AU2017238647B2 (en) 2021-12-09

Family

ID=59899752

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017238647A Active AU2017238647B2 (en) 2016-03-24 2017-03-24 Treatment of cancer with TG02

Country Status (12)

Country Link
US (2) US11865116B2 (enExample)
EP (1) EP3432888B1 (enExample)
JP (2) JP7026299B2 (enExample)
KR (2) KR20230020549A (enExample)
CN (2) CN115969854B (enExample)
AU (1) AU2017238647B2 (enExample)
ES (1) ES2941687T3 (enExample)
IL (1) IL261959B2 (enExample)
MX (3) MX2021012977A (enExample)
RU (1) RU2749025C2 (enExample)
SG (2) SG10202005621WA (enExample)
WO (1) WO2017165732A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
JP2020530454A (ja) 2017-08-07 2020-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 安全な細胞治療薬を生成するためのプラットフォーム
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02
WO2020190990A1 (en) * 2019-03-18 2020-09-24 The Board Of Regents Of The University Of Texas System Tumor-selective combination therapy
ES3034869T3 (en) * 2019-04-22 2025-08-25 Univ Pittsburgh Commonwealth Sys Higher Education Tg02 for use in treating gliomas in pediatric subjects
WO2021155580A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating cancer
US12264190B2 (en) * 2020-04-24 2025-04-01 Astrazeneca Ab Compositions and methods of treating cancer with chimeric antigen receptors
WO2022035723A1 (en) * 2020-08-10 2022-02-17 The Broad Institute, Inc. Compositions, panels, and methods for characterizing chronic lymphocytic leukemia
CA3238640A1 (en) * 2021-11-18 2023-05-25 Kishor Bhatia Method for treating cancer with acylfulvene and radiation
CN114113051B (zh) * 2021-12-16 2023-06-16 南京信息工程大学 一种psma电致化学发光传感器的制备方法及应用
EP4197525A1 (en) 2021-12-20 2023-06-21 Scandion Oncology A/S Combination of drugs for the treatment of cancer
CN114480639B (zh) * 2021-12-24 2022-09-30 中国医学科学院北京协和医院 新靶点用于诊断和治疗垂体腺瘤
WO2023143608A1 (zh) * 2022-01-30 2023-08-03 上海复东生物医药有限责任公司 一种组合物、其制备方法及应用
CN114518456B (zh) * 2022-02-17 2025-06-20 南京医科大学 一种通过diaph1蛋白预测肿瘤免疫治疗疗效的方法及试剂盒
WO2023242235A1 (en) 2022-06-14 2023-12-21 Scandion Oncology A/S Abcg2 inhibitor and nae inhibitor for the treatment of cancer
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153870A1 (en) * 2014-04-04 2015-10-08 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501692A (enExample) 1980-09-24 1982-09-16
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
EP0084796B1 (en) 1982-01-22 1990-05-02 Cetus Corporation Hla typing method and cdna probes used therein
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
DK1951730T3 (da) * 2005-11-16 2010-09-27 S Bio Pte Ltd Heteroalkylbundne pyrimidinderivater
US9120815B2 (en) * 2010-02-05 2015-09-01 Tragara Pharmaceuticals, Inc. Solid state forms of macrocyclic kinase inhibitors
UY34897A (es) * 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
WO2014161046A1 (en) * 2013-04-04 2014-10-09 The Walter And Eliza Hall Institute Of Medical Research Methods of treating diseases characterized by excessive wnt signalling
CN105492439B (zh) * 2013-06-21 2019-11-22 齐尼思表观遗传学有限公司 作为溴结构域抑制剂的取代的双环化合物
CN105451770B (zh) 2013-08-20 2020-02-07 默沙东公司 使用PD-1拮抗剂和dinaciclib的组合治疗癌症
US11013743B2 (en) * 2013-12-20 2021-05-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of CDK and ERK inhibitors
WO2015157093A1 (en) 2014-04-08 2015-10-15 Rigel Pharmaceuticals, Inc. 2,3-disubstituted pyridine compounds as tgf-beta inhibitors and methods of use
BR112017004826A2 (pt) 2014-09-13 2017-12-12 Novartis Ag terapias de combinação de inibidores de alk
ES2977589T3 (es) 2017-08-18 2024-08-27 Cothera Bioscience Inc Forma polimórfica de TG02

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153870A1 (en) * 2014-04-04 2015-10-08 Memorial Sloan-Kettering Cancer Center Method and kits for identifying of cdk9 inhibitors for the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOH et al., "TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti- leukemic properties", Leukemia, (2011-08-23), vol. 26, pages 236 - 243 *
HOFMEISTER et al., "TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients", Blood, (2015), vol. 126, page 3052 *
PALLIS M ET AL, "The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells.", BR J OF HAEM, OCT 2012, vol. 159(2), p 191 - 203 *
S. ALVAREZ-FERNANDEZ ET AL, "Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor", CLINICAL CANCER RESEARCH, US, (2013-05-15), vol. 19, no. 10, doi:10.1158/1078-0432.CCR-12-2118, ISSN 1078-0432, pages 2677 - 2687 *

Also Published As

Publication number Publication date
JP7026299B2 (ja) 2022-02-28
JP7459149B2 (ja) 2024-04-01
JP2022050631A (ja) 2022-03-30
EP3432888A4 (en) 2019-11-13
IL261959B1 (en) 2023-04-01
CN115969854B (zh) 2025-12-23
EP3432888A1 (en) 2019-01-30
SG10202005621WA (en) 2020-07-29
AU2017238647A1 (en) 2018-10-25
WO2017165732A1 (en) 2017-09-28
US20200323862A1 (en) 2020-10-15
CN109195603B (zh) 2022-11-08
US20240156824A1 (en) 2024-05-16
MX387283B (es) 2025-03-18
JP2019509354A (ja) 2019-04-04
IL261959B2 (en) 2023-08-01
ES2941687T3 (es) 2023-05-24
RU2749025C2 (ru) 2021-06-03
NZ746933A (en) 2025-03-28
CA3018875A1 (en) 2017-09-28
SG11201808306PA (en) 2018-10-30
MX2022008868A (es) 2022-08-11
RU2018137217A (ru) 2020-04-24
CN115969854A (zh) 2023-04-18
MX2021012977A (es) 2022-10-03
US11865116B2 (en) 2024-01-09
KR102491013B1 (ko) 2023-01-31
CN109195603A (zh) 2019-01-11
RU2018137217A3 (enExample) 2020-05-29
KR20190006948A (ko) 2019-01-21
EP3432888B1 (en) 2022-10-05
IL261959A (en) 2018-10-31
KR20230020549A (ko) 2023-02-10

Similar Documents

Publication Publication Date Title
US20240156824A1 (en) Treatment of cancer with tg02
US20240254141A1 (en) Polymorphic form of tg02 for treating cancer
CN111033631B (zh) 用于生成分子功能谱、对其进行可视化和分类的系统和方法
EP3430171B1 (en) Detection and treatment of anti-pd-1 therapy resistant metastatic melanomas
RU2745730C2 (ru) Способы классификации пациентов с солидным раком
Zhang et al. Identification of a Novel ECM Remodeling Macrophage Subset in AKI to CKD Transition by Integrative Spatial and Single‐Cell Analysis
US20220170940A1 (en) Biomarker with therapeutic implications for peritoneal carcinomatosis
CA3018875C (en) Treatment of cancer with tg02
US20240139175A1 (en) Combination therapy with a vinca alkaloid n-oxide and an immune checkpoint inhibitor
Oshima et al. Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: an exploratory biomarker study of COMPASS, a randomized phase II trial
HK40106713A (en) Polymorphic form of tg02
HK40025378A (en) Polymorphic form of tg02
HK40025378B (en) Polymorphic form of tg02
HK1261788B (en) Treatment of cancer with tg02
HK1261788A1 (en) Treatment of cancer with tg02
Gui et al. Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study
WO2024025923A1 (en) Methods for selection of cancer patients for anti-angiogenic and immune checkpoint blockade therapies and combinations thereof
Zhang et al. Unraveling the Microenvironment and the Pathogenic Axis of HIF‐1α–Visfatin–Fibrosis in Autoimmune Pancreatitis Using a Single‐Cell Atlas
EP3974541A1 (en) Composition for cancer diagnosis
Kurimoto et al. MYC/BCL2 double-hit Lymphoma in a patient with rheumatoid arthritis associated with methotrexate treatment
US12173039B1 (en) TPL2 inhibiting agents, uses thereof, and detection of TPL2
KR20190079801A (ko) 방사선 치료에 대한 직장암의 예후 예측용 조성물
Zhang Bioinformatic Analysis of Acute Respiratory Distress Syndrome and Sepsis Reveals Hypoxia Related Genes
Belle A Subset of Senescent Myofibroblasts Orchestrates Immunosuppression in Pancreatic Cancer
Li et al. Quercetin Induces Ferroptosis in Ovarian Cancer by Suppressing the NRF2/HO-1/GPX4 Axis and Increasing the Efficacy of Cisplatin

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: COTHERA BIOSCIENCE, INC.

Free format text: FORMER APPLICANT(S): TRAGARA PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)